In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Jose M CalderinDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, Cape Town, South Africa.ORCID 0000-0002-0310-6949 Sean WassermanWellcome Discovery Research Platforms in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa.ORCID 0000-0002-3508-6719 Rosleine Antilus-SainteCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States.
Melissa CristaldoCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States.
Narineh M OdjourianCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States.
Faye LanniCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States.
Firat KayaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States.
Noha AbdelgawadDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, Cape Town, South Africa.ORCID 0000-0002-4907-345X Juan Eduardo Resendiz-GalvanDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, Cape Town, South Africa.ORCID 0000-0001-9111-8052 Matthew ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States.ORCID 0000-0002-4390-3555 Veronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States.ORCID 0000-0001-9470-5009 Paolo DentiDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, Cape Town, South Africa.ORCID 0000-0001-7494-079X Martin GengenbacherCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States.ORCID 0000-0002-0208-5920 Funding
Translational approaches to improve understanding and outcome in Tuberculous meningitisR01AI145436 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI GENGENBACHER, MARTIN ALFONS, LAI, RACHEL PEI JEN · 2020 to 2024
$3.6MBill and Melinda Gates Foundation INV 052110NIAID NIH HHS R01 AI145436NIH HHS R01AI145436Wellcome Discovery Research Platform in Infection 226817/Z/22/ZWellcome Trust
6 · The paper itselfAbstract
Treatment optimization through pharmacokinetic evaluation is needed to improve outcomes in tuberculous meningitis (TBM). Clinical assessment of drug penetration into the central nervous system (CNS) is limited to cerebrospinal fluid (CSF) sampling, which may not reflect drug exposures at the site-of-disease. We characterized the pharmacokinetics of antituberculosis drugs in CNS tissues using a rabbit model of TBM. Rabbits infected with
Indexed as
Antitubercular AgentsCentral Nervous SystemTuberculosis, MeningealAnimalsChromatography, LiquidDiarylquinolinesDisease Models, AnimalFemaleIsoniazidLinezolidMycobacterium tuberculosisPyrazinamideRabbitsRifabutinRifampinTandem Mass SpectrometryAntitubercular AgentsbedaquilineDiarylquinolinesIsoniazidLinezolidPyrazinamideRifabutinRifampinbedaquilinecentral nervous systemcerebrospinal fluidisoniazidlinezolidnonlinear mixed-effects modelingpharmacokineticspyrazinamiderabbit modelrifabutinrifampicintuberculous meningitis
Identifiers
PMID42429967
PMCPMC13436124
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390